Clinical Study
Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months
Table 3
Type of drug, administrations, and doses linked to systemic pathology.
| | Pathology | Drug | Dosage |
| | Lung cancer + bone metastases | Zoledronate | 4 MG × 3 administrations every 28 days | | Prostate + bladder cancer + bone and lymph node metastases | Zoledronate | 4 MG × 3 administrations every 28 days | | Breast cancer + bone metastases | Zoledronate | 4 MG × 3 administrations every 28 days | | Breast cancer + bone and lymph node metastases | Zoledronate | 4 MG × 3 administrations every 28 days | | Lung cancer + bone metastases | Zoledronate | 4 MG × 5 administrations every 28 days | | Breast and colon cancer + bone metastases | Ibandronate | 2,5 mg by os/day | | Breast cancer + bone and lung metastases | Zoledronate | 4 MG × 3 administrations every 28 days | | Breast cancer + bone metastases | Ibandronate | 2,5 mg by os/day | | Breast cancer + bone metastases | Zoledronate | 4 MG × 3 administrations every 28 days | | Breast cancer + bone, pulmonary and hepatic metastases | Zoledronate | 4 MG × 3 administrations every 28 days |
|
|
